Fresenius Medical Care Sets May 21, 2026 AGM With Dividend and New Buyback Mandate on Agenda
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fresenius Medical Care ( (FMS) ) has provided an announcement.
On April 14, 2026, Fresenius Medical Care AG filed a Form 6-K outlining documents for its Annual General Meeting, to be held in person on May 21, 2026 in Frankfurt. The filing includes English translations of key reports for fiscal 2025, such as the compensation report, the Supervisory Board’s report, and an explanatory management report, along with the ADR voting instruction card.
At the AGM, shareholders will vote on a proposed dividend of EUR 1.49 per share for fiscal 2025, board and management discharge, auditor appointments for 2026, and approval of the 2025 compensation report. Management is also seeking a renewed authorization, valid until May 20, 2031, to buy back up to 10% of share capital, a move that would preserve financial flexibility for capital allocation and potential share-based measures, while dividend and auditor proposals signal continuity in governance and payout policy.
The most recent analyst rating on (FMS) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.
Spark’s Take on FMS Stock
According to Spark, TipRanks’ AI Analyst, FMS is a Neutral.
The score reflects moderate fundamentals with improving profitability and a stable balance sheet but weakening growth/cash-flow trends, a cautious 2026 outlook with meaningful headwinds despite strong execution initiatives, and a supportive valuation (modest P/E and solid dividend) alongside neutral-to-soft technical momentum.
To see Spark’s full report on FMS stock, click here.
More about Fresenius Medical Care
Fresenius Medical Care AG is a Germany-based healthcare company specializing in dialysis products and services for patients with chronic kidney failure. The group operates globally, providing dialysis treatments and related medical equipment, and is listed in Germany and the U.S., targeting both European and international capital markets through its share and ADR structures.
Average Trading Volume: 620,631
Technical Sentiment Signal: Hold
Current Market Cap: $13.78B
See more data about FMS stock on TipRanks’ Stock Analysis page.
